The Effect of Insulin on the Rise in Blood Pressure and Plasma Aldosterone after Angiotensin II in Normal Man

1983 ◽  
Vol 64 (4) ◽  
pp. 383-386 ◽  
Author(s):  
H. Vierhapper ◽  
W. Waldhäusl ◽  
P. Nowotny
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Serum Potassium ◽  
Intravenous Infusion ◽  
Serum Insulin ◽  
Plasma Aldosterone ◽  
Normal Man

1. The effect of an intravenous infusion of insulin [2.5 units h−1 (m2 of body surface area)−1] on the rise in blood pressure and plasma aldosterone after intravenous angiotensin II (5, 10, and 20 ng min−1 kg−1) was investigated in six healthy, sodium-loaded men. 2. Serum insulin reached 96.8 ± 18.1 μ-units/ml (control: 7.0 ± 1.5 μ-units/ml) and serum potassium fell from 4.2 ± 0.2 mmol/l to 3.6 ± 0.2 mmol/l (P < 0.005). 3. Hyperinsulinaemia increased (P < 0.05) the secretion of aldosterone during the largest dose of angiotensin II (20 ng min−1 kg−1), but had no effect on the rise in blood pressure after angiotensin II.

Doppler Transmitral Flow Velocity Parameters: Relationship between Age, Body Surface Area, Blood Pressure and Gender in Normal Subjects

1987 ◽  
Vol 1 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Julius M. Gardin ◽  
Mary K. Rohan ◽  
Dennis M. Davidson ◽  
Ali Dabestani ◽  
Mark Sklansky ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Flow Velocity ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Normal Subjects ◽  
Transmitral Flow ◽  
And Gender

INHIBITION OF ANGIOTENSIN III ACTION BY DES-ASP1-,ILEU8-ANGIOTENSIN II IN MAN

1978 ◽  
Vol 87 (2) ◽  
pp. 359-366
Author(s):  
Tsuyoshi Kono ◽  
Fumitake Ikeda ◽  
Fumimaro Oseko ◽  
Masataka Nanno ◽  
Hiroo Imura ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Adrenal Cortex ◽  
Intravenous Infusion ◽  
Inhibitory Effect ◽  
Plasma Aldosterone ◽  
Angiotensin Iii ◽  
Normal Men

ABSTRACT In 5 normal men intravenous infusion of 600 ng/kg/min of des-asp1-,ileu8-angiotensin II (AIIIA) inhibited a rise in blood pressure as well as increase in plasma aldosterone caused by an intravenous infusion of 20 or 100 ng/kg/min of des-asp1-angiotensin II (angiotensin III, AIII). This result and our previous study on simultaneous infusions of 600 ng/kg/min of AIIIA and 20 ng/kg/min of angiotensin II (All) in the same 5 normal men demonstrate that this dose of AIIIA antagonizes AIII and All on the adrenal cortex as well as peripheral arterioles and that AIIIA has the same degree of inhibitory effect on the aldosterone-stimulating action of AIII and on that of All in man.

Left Ventricular Hypertrophy in Adolescents with Elevated Blood Pressure: Assessment by Chest Roentgenography, Electrocardiography, and Echocardiography

PEDIATRICS ◽  
1981 ◽  
Vol 67 (2) ◽  
pp. 255-259
Author(s):  
W. Pennock Laird ◽  
David E. Fixler
Keyword(s):  
Blood Pressure ◽  
Left Ventricular Hypertrophy ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Elevated Blood ◽  
Control Subjects ◽  
Normotensive Control

The purpose of this study was to assess the prevalence of left ventricular hypertrophy in adolescents with persistently elevated blood pressures. Chest roentgenograms, electrocardiograms, and echocardiograms were performed on 50 adolescents with elevated blood pressure and 50 matched normotensive control subjects. No subject in either group demonstrated cardiomegaly on x-ray. Interpretation of the electrocardiograms indicated that similar numbers of both hypertensive (7/50) and control subjects (8/50) had ECG evidence of left ventricular hypertrophy. The echocardiograms showed that the mean left ventricular wall thickness (LVWT) in the hypertensive adolescents was 7.8 mm ± 0.1 (SE), compared with 6.5 ± 0.1 in the control subjects (P &lt; .001). When the measurements were indexed to body surface area, the difference remained highly significant. Indexed left ventricular mass (LVM)/body surface area (BSA) was also significantly greater (P &lt; .001) in the hypertensive (84.2 gm/sq m ± 2.1) than in the control subjects (72.0 ± 2.1). Using data from the normotensive control subjects, we defined the 95th percentile for both LVWT/BSA and LVM/BSA. Among hypertensive adolescents, 9/50 had LVWT/BSA and 8/50 had LVM/BSA above this level. For control subjects, only 1/50 had elevated LVWT/BSA values and 2/50 elevated LVM/BSA values. This study demonstrates that hypertensive adolescents have an increased prevalence of left ventricular hypertrophy and that echocardiography is the most useful noninvasive method to detect these changes.

scholarly journals Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer

PLoS ONE ◽  
2016 ◽  
Vol 11 (12) ◽  
pp. e0165262 ◽  
Author(s):  
Paul Kotwinski ◽  
Gillian Smith ◽  
Jackie Cooper ◽  
Julie Sanders ◽  
Louise Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Blood Pressure ◽  
Surface Area ◽  
Body Surface Area ◽  
Early Breast Cancer ◽  
Body Surface ◽  
Baseline Blood Pressure ◽  
Anthracycline Cardiotoxicity

The Hypotensive Effect of Propranolol in Captopril-Treated Patients Does Not Involve the Plasma Renin—Angiotensin—Aldosterone System

1981 ◽  
Vol 61 (s7) ◽  
pp. 441s-444s ◽  
Author(s):  
J. Staessen ◽  
R. Fagard ◽  
P. Lijnen ◽  
L. J. Verschueren ◽  
A. Amery
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Serum Potassium ◽  
Plasma Renin ◽  
Hypotensive Effect ◽  
Placebo Treatment ◽  
Plasma Aldosterone ◽  
Double Blind ◽  
Plasma Aldosterone Concentration ◽  
Plasma Angiotensin

1. With a double-blind cross-over protocol, 20 hypertensive captopril-treated patients were studied by adding in a variable sequence a placebo and propranolol (80 mg three times a day) to their captopril regimen (200 mg three times a day), during periods each lasting 1 month. During captopril—placebo treatment their diastolic blood pressure remained elevated between 90 and 114 mmHg. 2. The additional administration of propranolol produced a significant hypotensive effect, but no alterations of the plasma angiotensin II and aldosterone concentrations and of the urinary aldosterone excretion occurred. The present data indicate that in captopril-treated patients the hypotensive effect of propranolol is achieved independently of changes in the plasma angiotensin II and aldosterone concentration. 3. The additional administration of propranolol also produced an increase in the serum potassium levels in the absence of any change in the plasma aldosterone concentration or in the urinary aldosterone excretion.

scholarly journals How should renal hemodynamic data be indexed in obesity?

1995 ◽  
Vol 5 (9) ◽  
pp. 1709-1713 ◽  
Author(s):  
R E Schmieder ◽  
A H Beil ◽  
H Weihprecht ◽  
F H Messerli
Keyword(s):  
Blood Pressure ◽  
Regression Analysis ◽  
Multiple Regression Analysis ◽  
Surface Area ◽  
Body Surface Area ◽  
Arterial Blood Pressure ◽  
Body Surface ◽  
Normal Weight ◽  
Arterial Blood ◽  
Obese Subjects

Clearance data are customarily indexed to body surface area of 1.73 m2. This study examined whether this standard procedure gives correct values for renal perfusion in obese subjects. In 215 subjects who varied in age, gender, height, weight, obesity, and mean arterial blood pressure, RPF was determined by measuring the clearance of (131I)para-aminohippuric acid. Multiple regression analysis of the whole study group revealed that age (beta = -0.44, P < 0.001), height (beta = +0.25, P < 0.01), and arterial blood pressure (beta = -0.19, P < 0.01) were independent predictors of RPF, but that weight or body mass index was not. When related to body surface area, RPF appeared to decline with increasing obesity as follows: normal weight, 609 +/- 153 mL/min per 1.73 m2; overweight, 572 +/- 149 mL/min per 1.73 m2; severely overweight, 530 +/- 145 mL/min per 1.73 m2 (P < 0.012). In contrast, RPF related to height reflected a pattern concordant with the multiple regression analysis: normal weight, 3.76 +/- 0.9 mL/min per meter; overweight, 3.86 +/- 1.0 mL/min per meter; and severely overweight, 3.86 +/- 1.0 mL/min per meter (not significant). A separate repetition of the whole analysis for both normotensive (N = 55) and hypertensive subjects (N = 160) revealed a result similar to that found for the whole group. Thus, our results show that obesity was not a determinant of RPF, and when related to body surface area, inappropriately low values of RPF were calculated for obese patients. It was concluded that RPF values correlate with height and not with surface area in obese subjects.

Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer

2019 ◽  
Vol 29 (2) ◽  
pp. 341-345
Author(s):  
Robert D Morgan ◽  
Andrew R Clamp ◽  
Cong Zhou ◽  
Geoff Saunders ◽  
Nerissa Mescallado ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Intravenous Infusion ◽  
Objective Response ◽  
Platinum Resistance ◽  
Platinum Resistant ◽  
Third Line ◽  
Dose Dense

IntroductionStandard of care treatment for women who develop relapsed ovarian cancer includes sequential platinum- and/or paclitaxel-based chemotherapy, with reducing disease-free intervals. Once platinum resistance develops, treatment options become limited and dose-dense regimens may be offered. We report the efficacy and safety of dose-dense cisplatin with gemcitabine chemotherapy for relapsed platinum-resistant ovarian cancer.MethodsA retrospective analysis of all patients with relapsed, platinum-resistant ovarian, primary peritoneal or fallopian tube cancer treated with cisplatin 35 mg/m2 of body surface area by intravenous infusion with gemcitabine 1000 mg/m2 of body surface area by intravenous infusion on days 1 and 8 of every 21-day treatment cycle between 1 January 2009 and 1 June 2017.ResultsNinety-four eligible patients had received a median of three (range one–eight) prior lines of cytotoxic therapy for relapsed ovarian cancer. Sixty patients (64%) had received ≥ 1 prior dose-dense chemotherapy regimen. Dose-dense cisplatin with gemcitabine was associated with a median progression-free survival (PFS) of 4.4 months (95% CI 3.6 to 5.3) and overall survival of 7.6 months (95% CI 5.6 to 9.6). The median PFS for dose-dense cisplatin with gemcitabine as first- (n = 34), second- (n = 42), and third-line or later (n = 18) dose-dense therapy was 4.2 (95% CI 3.2 to 5.2), 5.0 (95% CI 3.5 to 6.5), and 4.2 (95% CI 3.3 to 5.1) months respectively. The RECIST objective response rate for first-, second-, and third-line dose-dense cisplatin with gemcitabine was 23%, 14 %, and 7 % respectively. The most common grade 3 – 4 adverse events were thrombocytopenia (20%), anemia (18%), and neutropenia (14%).DiscussionDose-dense cisplatin with gemcitabine provides modest efficacy whether it is used as a first- or subsequent line of dose-dense chemotherapy to treat relapsed platinum-resistant ovarian cancer and the toxicity is manageable with supportive measures.

Blood pressure load per body surface area is higher in women than in men

2020 ◽  
Author(s):  
Päivi E. Korhonen ◽  
Samuel Palmu ◽  
Hannu Kautiainen ◽  
Johan G. Eriksson
Keyword(s):  
Blood Pressure ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Pressure Load ◽  
Blood Pressure Load

Device for Regulating Intravenous Infusion

PEDIATRICS ◽  
1957 ◽  
Vol 19 (2) ◽  
pp. 342-343
Author(s):  
DAVID B. SHURTLEFF
Keyword(s):  
New England ◽  
Surface Area ◽  
Body Surface Area ◽  
Critically Ill ◽  
Body Surface ◽  
Critically Ill Patients ◽  
Intravenous Infusion ◽  
Free Water ◽  
Critical Periods ◽  
Intravenous Fluid Administration

Clinical and metabolic studies have PEDIATRIC I.V. DRIP [SEE FIG I. IN SOURCE PDF] indicated that critically ill patients may lose temporarily a major portion of their usual tolerance for water and certain electrolytes (New England J. Med., 252:856, 1955). As a result, they are apt to become water-intoxicated if given too much solute-free water and salt-intoxicated if given too much saline, especially during the operative and immediate postoperative periods. It would appear that one simple way to avoid these difficulties is to keep the rate of intravenous fluid administration down to approximately 1200 ml/m2 of body surface area per 24 hours during such critical periods. In the adult of 1.8 m2 (70 kg), this rate of administration would mean the delivery of an absolute total of about 2200 ml/day.

Sign in / Sign up

Export Citation Format

Share Document